NCT00912860View on ClinicalTrials.gov

Immunogenicity and Safety Study of Serum-Free Avonex

PHASE2CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

January 31, 2005

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon beta-1a

serum free Avonex given IM once a week

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY